IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Stephens. They set an "overweight" rating and a $51.00 price target on the stock.
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer [Yahoo! Finance]
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise